Your browser doesn't support javascript.
loading
Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.
Ando, Koji; Shah, Ankur K; Sachdev, Vibhu; Kleinstiver, Benjamin P; Taylor-Parker, Julian; Welch, Moira M; Hu, Yiheng; Salgia, Ravi; White, Forest M; Parvin, Jeffrey D; Ozonoff, Al; Rameh, Lucia E; Joung, J Keith; Bharti, Ajit K.
Afiliação
  • Ando K; Department of Medicine, Division of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
  • Shah AK; Department of Medicine, Division of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
  • Sachdev V; Department of Medicine, Division of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
  • Kleinstiver BP; Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
  • Taylor-Parker J; Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA.
  • Welch MM; Department of Medicine, Division of Hematology Oncology, Boston University School of Medicine, Boston, MA, USA.
  • Hu Y; Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
  • Salgia R; Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
  • White FM; Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte , CA, USA.
  • Parvin JD; Department of Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Ozonoff A; Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
  • Rameh LE; Center for Patient Safety and Quality Research, Boston Children's Hospital, Boston, MA, USA.
  • Joung JK; Department of Medicine, Obesity Research Center, Boston University School of Medicine, Boston, MA, USA.
  • Bharti AK; Molecular Pathology Unit, Massachusetts General Hospital, Charlestown, Massachusetts, USA.
Oncotarget ; 8(27): 43733-43751, 2017 Jul 04.
Article em En | MEDLINE | ID: mdl-28415827
ABSTRACT
Proteasomal degradation of topoisomerase I (topoI) is one of the most remarkable cellular phenomena observed in response to camptothecin (CPT). Importantly, the rate of topoI degradation is linked to CPT resistance. Formation of the topoI-DNA-CPT cleavable complex inhibits DNA re-ligation resulting in DNA-double strand break (DSB). The degradation of topoI marks the first step in the ubiquitin proteasome pathway (UPP) dependent DNA damage response (DDR). Here, we show that the Ku70/Ku80 heterodimer binds with topoI, and that the DNA-dependent protein kinase (DNA-PKcs) phosphorylates topoI on serine 10 (topoI-pS10), which is subsequently ubiquitinated by BRCA1. A higher basal level of topoI-pS10 ensures rapid topoI degradation leading to CPT resistance. Importantly, PTEN regulates DNA-PKcs kinase activity in this pathway and PTEN deletion ensures DNA-PKcs dependent higher topoI-pS10, rapid topoI degradation and CPT resistance.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Camptotecina / DNA Topoisomerases Tipo I / Resistencia a Medicamentos Antineoplásicos / Ubiquitina / Complexo de Endopeptidases do Proteassoma / Inibidores da Topoisomerase I Limite: Humans Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Camptotecina / DNA Topoisomerases Tipo I / Resistencia a Medicamentos Antineoplásicos / Ubiquitina / Complexo de Endopeptidases do Proteassoma / Inibidores da Topoisomerase I Limite: Humans Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos